Posted 02 April, 2024
Bluejay Diagnostics, Inc. appointed new CEO
CEO Change detected for ticker Nasdaq:BJDX in a 8-K filed on 02 April, 2024.
In connection therewith, Frances Scally, who had served as the Company's Interim Chief Financial Officer pursuant to such agreements with DLA, ceased serving as an officer of the Company. In connection with these matters, the Board of Directors of the Company (the "Board") has designated Neil Dey, the Company's President and Chief Executive Officer, as the Company's the principal financial and accounting officer, in addition to serving as principal executive officer.
$986K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 29, 2024, Bluejay Diagnostics, Inc. (the "Company") provided notice to DLA, LLC ("DLA") that the Company has terminated the scope of work and master services agreement between the Company and DLA, effective immediately. In connection therewith, Frances Scally, who had served as the Company's Interim Chief Financial Officer pursuant to such agreements with DLA, ceased serving as an officer of the Company. In connection with these matters, the Board of Directors of the Company (the "Board") has designated Neil Dey, the Company's President and Chief Executive Officer, as the Company's the principal financial and accounting officer, in addition to serving as principal executive officer.
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.